A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Recruiting

Phase 3

Bomedemstat vs. BATA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06079879

Conditions

Essential Thrombocythemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bomedemstat

Anagrelide

Busulfan

Interferon alfa/pegylated interferon alfa

Ruxolitinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-05-31.